The truth is out there: An overall perspective on androgen deprivation

Beth A. Hellerstedt; Kenneth J. Pienta

doi:10.1016/S1078-1439(03)00046-2

The truth is out there: An overall perspective on androgen deprivation

Beth A. Hellerstedt, Kenneth J. Pienta

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.

Original language	English (US)
Pages (from-to)	272-281
Number of pages	10
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/S1078-1439(03)00046-2
State	Published - Jul 2003
Externally published	Yes

Keywords

ADT
Adjuvant
Cost
LHRH agonist
Neoadjuvant

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/S1078-1439(03)00046-2

Cite this

@article{62f1abbe55c4411db40db2ae16944533,

title = "The truth is out there: An overall perspective on androgen deprivation",

abstract = "Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.",

keywords = "ADT, Adjuvant, Cost, LHRH agonist, Neoadjuvant",

author = "Hellerstedt, {Beth A.} and Pienta, {Kenneth J.}",

year = "2003",

month = jul,

doi = "10.1016/S1078-1439(03)00046-2",

language = "English (US)",

volume = "21",

pages = "272--281",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - The truth is out there

T2 - An overall perspective on androgen deprivation

AU - Hellerstedt, Beth A.

AU - Pienta, Kenneth J.

PY - 2003/7

Y1 - 2003/7

N2 - Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.

AB - Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.

KW - ADT

KW - Adjuvant

KW - Cost

KW - LHRH agonist

KW - Neoadjuvant

UR - http://www.scopus.com/inward/record.url?scp=0142217935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142217935&partnerID=8YFLogxK

U2 - 10.1016/S1078-1439(03)00046-2

DO - 10.1016/S1078-1439(03)00046-2

M3 - Article

C2 - 12954498

AN - SCOPUS:0142217935

SN - 1078-1439

VL - 21

SP - 272

EP - 281

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 4

ER -

The truth is out there: An overall perspective on androgen deprivation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this